{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:54:30Z","timestamp":1795089270566,"version":"4.10.2"},"reference-count":134,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.<\/jats:p>","DOI":"10.1182\/blood-2016-03-643544","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:20:10Z","timestamp":1460420410000},"page":"2391-2405","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8408,"title":["The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia"],"prefix":"10.1182","volume":"127","author":[{"given":"Daniel A.","family":"Arber","sequence":"first","affiliation":[{"name":"Department of Pathology, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Thiele","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Le Beau","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara D.","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Vardiman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111903394943200_B1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111903394943200_B2","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","article-title":"Chronic myelogenous leukemia, version 1.2015.","volume":"12","author":"O\u2019Brien","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2019111903394943200_B3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111903394943200_B4","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s00277-015-2331-1","article-title":"CML--Where do we stand in 2015?","volume":"94","author":"Hehlmann","year":"2015","journal-title":"Ann Hematol"},{"key":"2019111903394943200_B5","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.14694\/EdBook_AM.2015.35.e381","article-title":"Diagnosing and managing advanced chronic myeloid leukemia.","volume":"35","author":"Deininger","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2019111903394943200_B6","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"16","key":"2019111903394943200_B7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111903394943200_B8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"2019111903394943200_B9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903394943200_B10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study.","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111903394943200_B11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.24288","article-title":"Myeloproliferative neoplasms: Morphology and clinical practice.","volume":"91","author":"Barbui","year":"2016","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111903394943200_B12","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111903394943200_B13","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111903394943200_B14","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria [published online ahead of print December 29, 2015].","author":"Gisslinger","journal-title":"Leukemia"},{"issue":"4","key":"2019111903394943200_B15","doi-asserted-by":"crossref","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"2019111903394943200_B16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.","volume":"88","author":"Madelung","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111903394943200_B17","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111903394943200_B18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/modpathol.2013.196","article-title":"Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.","volume":"27","author":"Gianelli","year":"2014","journal-title":"Mod Pathol"},{"issue":"1","key":"2019111903394943200_B19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"7","key":"2019111903394943200_B20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal.","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"6","key":"2019111903394943200_B21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111903394943200_B22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111903394943200_B23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111903394943200_B24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2019111903394943200_B25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia.","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111903394943200_B26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group\u2019s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms.","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"19","key":"2019111903394943200_B27","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia.","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903394943200_B28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"2019111903394943200_B29","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"26","key":"2019111903394943200_B30","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111903394943200_B31","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903394943200_B32","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111903394943200_B33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"issue":"6","key":"2019111903394943200_B34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111903394943200_B35","first-page":"766","article-title":"Chronic myelomonocytic leukemia.","volume":"4","author":"Storniolo","year":"1990","journal-title":"Leukemia"},{"issue":"2","key":"2019111903394943200_B36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease.","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"issue":"11","key":"2019111903394943200_B37","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/modpathol.2015.100","article-title":"Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.","volume":"28","author":"Boiocchi","year":"2015","journal-title":"Mod Pathol"},{"issue":"17","key":"2019111903394943200_B38","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms.","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111903394943200_B39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"2019111903394943200_B40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2019111903394943200_B41","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms.","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111903394943200_B42","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111903394943200_B43","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.","volume":"30","author":"Bejar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903394943200_B44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111903394943200_B45","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood.V85.7.1742.bloodjournal8571742","article-title":"Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system.","volume":"85","author":"Passmore","year":"1995","journal-title":"Blood"},{"issue":"10","key":"2019111903394943200_B46","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases.","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2019111903394943200_B47","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.leu.2404564","article-title":"A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification.","volume":"21","author":"Verburgh","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"2019111903394943200_B48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2012.02.014","article-title":"Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the D\u00fcsseldorf Registry on myelodysplastic syndromes.","volume":"36","author":"Germing","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"2019111903394943200_B49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.leukres.2012.09.021","article-title":"Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.","volume":"37","author":"Maassen","year":"2013","journal-title":"Leuk Res"},{"issue":"4","key":"2019111903394943200_B50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2019111903394943200_B51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-012-1565-4","article-title":"Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.","volume":"92","author":"Font","year":"2013","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111903394943200_B52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3324\/haematol.2011.056879","article-title":"Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.","volume":"97","author":"Parmentier","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2019111903394943200_B53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111903394943200_B54","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111903394943200_B55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111903394943200_B56","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.391","article-title":"Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.","volume":"26","author":"Germing","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2019111903394943200_B57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2010.231","article-title":"Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.","volume":"25","author":"Mallo","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111903394943200_B58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.","volume":"30","author":"Schanz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903394943200_B59","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes.","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111903394943200_B60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2019111903394943200_B61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903394943200_B62","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903394943200_B63","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111903394943200_B64","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes.","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111903394943200_B65","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2013.085217","article-title":"Clinical and genetic predictors of prognosis in myelodysplastic syndromes.","volume":"99","author":"Bejar","year":"2014","journal-title":"Haematologica"},{"issue":"25","key":"2019111903394943200_B66","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111903394943200_B67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.12354","article-title":"Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.","volume":"162","author":"Mallo","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111903394943200_B68","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"issue":"15","key":"2019111903394943200_B69","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111903394943200_B70","doi-asserted-by":"crossref","first-page":"e0126555","DOI":"10.1371\/journal.pone.0126555","article-title":"Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts.","volume":"10","author":"del Rey","year":"2015","journal-title":"PLoS One"},{"key":"2019111903394943200_B71","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.","volume":"6","author":"Gerstung","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"2019111903394943200_B72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2019111903394943200_B73","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1182\/blood-2012-03-415356","article-title":"Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts.","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"2019111903394943200_B74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/nyas.12346","article-title":"Familial myelodysplastic syndrome\/acute leukemia syndromes: a review and utility for translational investigations.","volume":"1310","author":"West","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2019111903394943200_B75","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111903394943200_B76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"4","key":"2019111903394943200_B77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111903394943200_B78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.","volume":"127","author":"Soupir","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2019111903394943200_B79","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111903394943200_B80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12301","article-title":"Does BCR\/ABL1 positive acute myeloid leukaemia exist?","volume":"161","author":"Nacheva","year":"2013","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111903394943200_B81","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903394943200_B82","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903394943200_B83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia.","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111903394943200_B84","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","article-title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.","volume":"113","author":"Wouters","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111903394943200_B85","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.bjc.6604977","article-title":"Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.","volume":"100","author":"Pabst","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"2019111903394943200_B86","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.bjc.6605207","article-title":"Reply to \u2018Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis\u2019.","volume":"101","author":"Hou","year":"2009","journal-title":"Br J Cancer"},{"issue":"16","key":"2019111903394943200_B87","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","article-title":"Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.","volume":"28","author":"Green","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903394943200_B88","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3324\/haematol.2010.031336","article-title":"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.","volume":"96","author":"Hollink","year":"2011","journal-title":"Haematologica"},{"issue":"18","key":"2019111903394943200_B89","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111903394943200_B90","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1182\/blood-2010-09-307314","article-title":"The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status.","volume":"116","author":"D\u00edaz-Bey\u00e1","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111903394943200_B91","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/blood-2011-12-395574","article-title":"Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.","volume":"119","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111903394943200_B92","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2009-11-255976","article-title":"RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.","volume":"117","author":"Schnittger","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2019111903394943200_B93","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","article-title":"AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.","volume":"114","author":"Tang","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111903394943200_B94","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","article-title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.","volume":"30","author":"Mendler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111903394943200_B95","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111903394943200_B96","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-014-2100-6","article-title":"Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.","volume":"93","author":"Rozman","year":"2014","journal-title":"Ann Hematol"},{"issue":"9","key":"2019111903394943200_B97","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2019111903394943200_B98","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","article-title":"AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.","volume":"114","author":"Haferlach","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111903394943200_B99","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2013-05-503847","article-title":"The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.","volume":"122","author":"Schlenk","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111903394943200_B100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"2019111903394943200_B101","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/blood-2012-10-462440","article-title":"Significance of FAB subclassification of \u201cacute myeloid leukemia, NOS\u201d in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.","volume":"121","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111903394943200_B102","doi-asserted-by":"crossref","first-page":"e41485","DOI":"10.1371\/journal.pone.0041485","article-title":"Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML.","volume":"7","author":"Zuo","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2019111903394943200_B103","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/leu.2013.144","article-title":"Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics.","volume":"27","author":"Grossmann","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111903394943200_B104","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3324\/haematol.2011.050526","article-title":"Acute myeloid leukemia with expanded erythropoiesis.","volume":"96","author":"Porwit","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"2019111903394943200_B105","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2009-09-243964","article-title":"Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.","volume":"115","author":"Hasserjian","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111903394943200_B106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1309\/AJCPRKYAT6EZQHC7","article-title":"Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities.","volume":"144","author":"Wang","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2019111903394943200_B107","first-page":"265","article-title":"Granulocytic sarcoma: a systematic review.","volume":"3","author":"Yilmaz","year":"2013","journal-title":"Am J Blood Res"},{"issue":"4","key":"2019111903394943200_B108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.siny.2012.02.010","article-title":"Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.","volume":"17","author":"Roy","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"2","key":"2019111903394943200_B109","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children\u2019s Cancer Group Studies 2861 and 2891.","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111903394943200_B110","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders.","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"2019111903394943200_B111","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111903394943200_B112","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/leu.2010.119","article-title":"Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification.","volume":"24","author":"van den Ancker","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2019111903394943200_B113","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-014-1531-0","article-title":"Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.","volume":"99","author":"Kawajiri","year":"2014","journal-title":"Int J Hematol"},{"issue":"4","key":"2019111903394943200_B114","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12343","article-title":"Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.","volume":"93","author":"Shimizu","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111903394943200_B115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia.","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"2019111903394943200_B116","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/gcc.22163","article-title":"Acute lymphoblastic leukemia with low hypodiploid\/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.","volume":"53","author":"M\u00fchlbacher","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2019111903394943200_B117","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"issue":"27","key":"2019111903394943200_B118","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1200\/JCO.2013.49.1308","article-title":"Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children\u2019s oncology group studies: a report from the children\u2019s oncology group.","volume":"31","author":"Heerema","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903394943200_B119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111903394943200_B120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903394943200_B121","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG\/Erasmus MC and COG\/St. Jude signatures.","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2019111903394943200_B122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"26","key":"2019111903394943200_B123","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111903394943200_B124","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903394943200_B125","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903394943200_B126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.beha.2010.08.002","article-title":"Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.","volume":"23","author":"Meijerink","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2019111903394943200_B127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PAP.0b013e31828d17ec","article-title":"Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma.","volume":"20","author":"Ohgami","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"2019111903394943200_B128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111903394943200_B129","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood-2012-11-465138","article-title":"Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.","volume":"121","author":"Neumann","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111903394943200_B130","doi-asserted-by":"crossref","first-page":"e53190","DOI":"10.1371\/journal.pone.0053190","article-title":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.","volume":"8","author":"Neumann","year":"2013","journal-title":"PLoS One"},{"issue":"7380","key":"2019111903394943200_B131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"3","key":"2019111903394943200_B132","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15.","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111903394943200_B133","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111903394943200_B134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434 [abstract].","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/blood-2016-06-721662","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/20\/2391\/1393154\/2391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/20\/2391\/1393154\/2391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:40:44Z","timestamp":1574134844000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/20\/2391\/35255\/The-2016-revision-to-the-World-Health-Organization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":134,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,5,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-643544","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}